These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 17306783

  • 21. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
    Kinoshita M, Kodera Y, Hibi K, Nakayama G, Inoue T, Ohashi N, Ito Y, Koike M, Fujiwara M, Nakao A.
    Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211
    [Abstract] [Full Text] [Related]

  • 22. Targeted therapy: overcoming drug resistance with clinical cancer genome.
    Ziogas DE, Katsios CS, Tzaphlidou M, Roukos DH.
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399
    [No Abstract] [Full Text] [Related]

  • 23. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs.
    Fojo T.
    Drug Resist Updat; 2007 Jul; 10(1-2):59-67. PubMed ID: 17350322
    [Abstract] [Full Text] [Related]

  • 24. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV.
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [Abstract] [Full Text] [Related]

  • 25. Overcoming drug resistance in patients with metastatic breast cancer.
    Wong ST, Goodin S.
    Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
    [Abstract] [Full Text] [Related]

  • 26. DNA methylation and sensitivity to antimetabolites in cancer cell lines.
    Sasaki S, Kobunai T, Kitayama J, Nagawa H.
    Oncol Rep; 2008 Feb; 19(2):407-12. PubMed ID: 18202788
    [Abstract] [Full Text] [Related]

  • 27. Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine.
    Workman P, de Bono J.
    Curr Opin Pharmacol; 2008 Aug; 8(4):359-62. PubMed ID: 18678282
    [No Abstract] [Full Text] [Related]

  • 28. [Problems associated with molecular targeted drugs for cancer].
    Kawaishi M, Koizum F, Nishio K.
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1373-9. PubMed ID: 17033223
    [Abstract] [Full Text] [Related]

  • 29. Cancer and natural selection.
    Fillon M.
    J Natl Cancer Inst; 2012 Dec 05; 104(23):1773-4. PubMed ID: 23213180
    [No Abstract] [Full Text] [Related]

  • 30. The search for optimal response prediction in cancer leads to a personalized approach.
    Van Cutsem E, Ciardiello F.
    Target Oncol; 2010 Mar 05; 5(1):3-4. PubMed ID: 20349283
    [No Abstract] [Full Text] [Related]

  • 31. Calculated resistance in cancer.
    Sawyers CL.
    Nat Med; 2005 Aug 05; 11(8):824-5. PubMed ID: 16079872
    [No Abstract] [Full Text] [Related]

  • 32. Do beta-tubulin mutations have a role in resistance to chemotherapy?
    Berrieman HK, Lind MJ, Cawkwell L.
    Lancet Oncol; 2004 Mar 05; 5(3):158-64. PubMed ID: 15003198
    [Abstract] [Full Text] [Related]

  • 33. Preface: National Cancer Act.
    Smalley KS.
    Adv Pharmacol; 2012 Mar 05; 65():xi-xiii. PubMed ID: 22959037
    [No Abstract] [Full Text] [Related]

  • 34. [Supragenomic strategies. Cancer research after HUGO].
    Fransson LA.
    Lakartidningen; 2001 Nov 07; 98(45):4976-8. PubMed ID: 11816899
    [Abstract] [Full Text] [Related]

  • 35. First results of largest study of genomes and cancer treatments available.
    Future Oncol; 2010 Sep 07; 6(9):1373. PubMed ID: 20919822
    [No Abstract] [Full Text] [Related]

  • 36. Targets for treatment success.
    Simon R.
    Nat Clin Pract Oncol; 2006 Jan 07; 3(1):1. PubMed ID: 16407857
    [No Abstract] [Full Text] [Related]

  • 37. [Role of endogenous iron in tumor sensitization to antitumor therapy].
    Chekhun VF, Shpilevaia SI.
    Vopr Onkol; 2010 Jan 07; 56(3):251-61. PubMed ID: 20804045
    [No Abstract] [Full Text] [Related]

  • 38. Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.
    Imyanitov EN, Iyevleva AG.
    Cancer Lett; 2022 Feb 01; 526():41-52. PubMed ID: 34808283
    [Abstract] [Full Text] [Related]

  • 39. Targeting oncogenes and tumor suppressors genes to mitigate chemoresistance.
    Fatemian T, Chowdhury EH.
    Curr Cancer Drug Targets; 2014 Feb 01; 14(7):599-609. PubMed ID: 25308718
    [Abstract] [Full Text] [Related]

  • 40. Taking advantage of drug resistance, a new approach in the war on cancer.
    Wang L, Bernards R.
    Front Med; 2018 Aug 01; 12(4):490-495. PubMed ID: 30022460
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.